CA2537610A1 - Pharmaceutical composition, method of manufacturing and therapeutic use thereof - Google Patents
Pharmaceutical composition, method of manufacturing and therapeutic use thereof Download PDFInfo
- Publication number
- CA2537610A1 CA2537610A1 CA002537610A CA2537610A CA2537610A1 CA 2537610 A1 CA2537610 A1 CA 2537610A1 CA 002537610 A CA002537610 A CA 002537610A CA 2537610 A CA2537610 A CA 2537610A CA 2537610 A1 CA2537610 A1 CA 2537610A1
- Authority
- CA
- Canada
- Prior art keywords
- oxaliplatin
- animal origin
- alcoholic
- pharmaceutical composition
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 title description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 34
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 34
- 241001465754 Metazoa Species 0.000 claims abstract description 23
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 22
- 238000004108 freeze drying Methods 0.000 claims abstract description 22
- 235000000346 sugar Nutrition 0.000 claims abstract description 21
- 150000008163 sugars Chemical class 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 5
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 8
- 239000000243 solution Substances 0.000 description 20
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 238000011109 contamination Methods 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000005336 cracking Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a pharmaceutical composition prepared by freeze-drying in vacuo, containing oxaliplatin as the active component and a pharmaceutically acceptable carrier, wherein the carrier is at least one alcoholic sugar of non-animal origin, the weight ratio of oxaliplatin to the alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin being 1:3 to 1:7. The invention also relates to the method of manufacturing of said composition and to the use of this composition in the treatment of tumors sensitive to oxaliplatin.
Description
Pharmaceutical Composition, Method of Manufacturing and Therapeutic Use Thereof Field of the Invention The invention relates to a pharmaceutical composition which is prepared by freeze-drying and contains oxaliplatin as the active component and a pharmaceutically acceptable carrier, application of this composition reducing the risk of viral contamination, especially by causers of animal spongiform encephalopathy.
Background of the Invention Oxaliplatin (named according to the INN nomenclature as oxaliplatinum) has been prepared for the first time in the optically pure form in 1978 by isolation from a mixture of isomers [ J.
Clin. Hematol. Oncol. 1977, 7(1), 197-210]. Oxaliplatin is chemically the {trans-(-)-1,2-cyclohexanediamine}-(oxalato)platinum(II) complex of formula I
O
(I) 'NH2 O
Oxaliplatin is a cytostatic agent used in treatment of testicular and ovarial tumors, malignant melanoma, bronchogenic carcinoma and especially of metastazing colon carcinoma in combination with fluoropyrimidines. In comparison with the hitherto used cisplatinum, oxaliplatin exhibits lower nefrotoxicity and a broader spectrum of antitumor activity.
Oxaliplatin is generally applied in doses 100 to 135 mg/m2 in the form of 2 to 6 hours' infusion. The infusion solution is prepared by dilution of the final drug form with 5% aqueous solution of glucose.
Within the framework of the prior art there was described a series of liquid drug forms of oxaliplatin based on its aqueous solutions which however for their insufficient stability so far have not found application. The cause of this instability is the known fact that oxaliplatin hydrolytically decomposes under formation of toxic platinum aquacomplexes. The only stable drug form of oxaliplatin known so far is a powder composition obtained by freeze-drying in vacuo (lyophilization). Beside oxaliplatin, this dry powdery composition contains a carrier consisting of lactose which ensures the cohesion of the dry oxaliplatin matrix formed by freeze-drying in vacuo and prevents its cracking, which otherwise would result in escape of part of the oxaliplatin from vials in which the freeze-drying takes place. The substantial drawback of the hitherto used lactose carrier, which is an animal product, is the risk of viral contamination of the pharmaceutical composition by viruses that may be present in lactose.
Recently, reduction of the risk of such viral contamination, especially of transfer of animal spongiform encephalopathy, represents a current problem concerning most drug forms that contain auxiliary components of animal, particularly bovine origin. Lactose, hitherto employed in oxaliplatin pharmaceutical compositions, exhibits very good cryoprotective effects and its replacement with another suitable carrier under preservation of properties of oxaliplatin lyophilizate and economy of the freeze-drying process so far has not been satisfactorily solved.
Summary of the Invention The above-mentioned desired replacement of the lactose carrier with another carrier which in principle eliminates the mentioned risk of viral contamination is solved by the pharmaceutical composition according to the present invention, prepared by freeze-drying in vacuo, that contains oxaliplatin as the active component together with a pharmaceutically acceptable carrier, the said composition being characterized in that it contains at least one alcoholic sugar of non-animal origin as a Garner, the ratio of oxaliplatin to this alcoholic sugar or alcoholic sugars of non-animal origin being 1:3 to 1:7 by weight.
Preferably, the pharmaceutical composition according to the invention contains oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin in a ratio 1:5 by weight.
In a pharmaceutical composition according to the invention, the preferred alcoholic sugar of non-animal origin is mannitol.
The present invention also relates to the method of manufacturing of the above mentioned pharmaceutical composition, characterized in that a sterile aqueous solution of oxaliplatin and of at least one alcoholic sugar of non-animal origin, containing oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of no-animal origin in a weight ratio 1:3 to 1:7 with total concentration of the mentioned compounds 2.8 to 3.2 % by weight, is introduced into a vial in a volume equal to at most 60 % of the available vial volume, whereupon the content of the vial is cooled to 2 to 8 °C, then freezed under linear temperature drop of 0.1 to 0.5 °C/min to a final temperature of -35 to -45 °C, left aside at this temperature for 1 to 6 hours and then subjected to freeze-drying in vacuo.
Finally, the invention also relates to the above mentioned pharmaceutical composition for application in treatment of tumors sensitive to oxaliplatin.
After dissolution in a suitable pharmaceutically acceptable solvent, the pharmaceutical composition according to this invention affords a clear solution which contains neither undissolved material nor turbidity and which is thus particularly suitable for parenteral application. The composition according to the invention can be readily prepared, is highly stable and its application does not represent any risk of viral contamination.
The method according to the present invention solves problems that would occur in the case of mere replacement of lactose by mannitol without changing the existing mode of working with lactose. During workup of solutions in which lactose is simply replaced with mannitol, the lyophilizate often escapes from the vials and the glass vials crack as the result of increased mechanical tension due to the changing volume of the freezed solution, which is particularly manifested by falling away of the vial bottom during the freeze-drying procedure.
It has been found that the temperature mode of the freezing procedure according to the invention significantly eliminates the mentioned vial cracking in the course of the freeze-drying procedure. Thus, it was found that in order to achieve an optimal freeze-drying rate the total concentration of oxaliplatin and of at least one alcoholic sugar in the aqueous solution before the freeze-drying must be 2.8 to 3.2 % by weight. Further, it was found that the vials can be filled with the sterile solution of oxaliplatin and mannitol in the mentioned weight ratio in a volume up to 60 % of the available vial volume without change of the lyophilizate quality, without escape of the lyophilizate from the vials, and without cracking of the vials, which represents a very advantageous solution from the viewpoint of utilization of capacity of the freeze-drying equipment.
For its properties, the pharmaceutical composition according to the invention is particularly suitable for application in treatment of tumors sensitive to oxaliplatin.
In the following part of the description the invention will be explained in detail using individual examples of execution, that are only illustrative, without limiting in any way the scope of the invention.
Examples Example 1 Under GMP conditions, 0.50 kg of oxaliplatin (pharmacopoeia quality) and 2.50 kg of mannitol (pharmacopoeia quality) are gradually dissolved at 20 to 25 °C
in 70 kg of water.
The obtained solution is sterilized by filtration through a 0.22 ~.m filter and filled into colourless clear vials for antibiotics of the first hydrolytic class, type 20 H (Saint Gobain Desjonqueres) the amount of the solution corresponding to 50 mg of the dissolved active component per vial. The filled vials are equipped with stoppers for freeze-drying and placed into a freeze-drying chamber, pre-cooled to 5 °C. After thermal equilibration of the solution in the vial with the environment, the solution in the vial is slowly freezed (linear temperature drop of 0.2 °C/min) to the final temperature of -40 °C. The frozen solution is left at this temperature for 4 h, whereupon it is subjected to freeze-drying in vacuo.
The obtained lyophilizate has a white compact form and contains 0.8 % by weight of water.
Dissolution of the obtained material gives a clear solution, in accord with Ph. Eur. Art. 2.2.1.
Example 2 Under GMP conditions, 0.50 kg of oxaliplatin (pharmacopoeia quality) and 2.50 kg of mannitol (pharmacopoeia quality) are gradually dissolved at 20 to 25 °C
in 70 kg of water.
The obtained solution is sterilized by filtration through a 0.22 pm filter and filled into colourless clear vials for antibiotics of the first hydrolytic class, type 20 H (Saint Gobain Desjonqueres) the amount of the solution corresponding to 100 mg of the dissolved active component per vial. The filled vials are equipped with stoppers for freeze-drying and placed into a freeze-drying chamber, pre-cooled to 5 °C. After thermal equilibration of the solution in the vial with the environment, the solution in the vial is slowly freezed (linear temperature drop of 0.2 °C/min) to the final temperature of -40 °C. The frozen solution is left at this temperature for 4 h, whereupon it is subjected to freeze-drying in vacuo.
The obtained lyophilizate has a white compact form and contains 1.0 % by weight of water.
Dissolution of the obtained material gives a clear solution, in accord with Ph. Eur. Art. 2.2.1.
Example 3 This Example studies the stability of the pharmaceutical composition prepared in Example 1 when stored at 40 °C and 75% relative humidity. The obtained results are given in Table below.
Table 1 Parameter evaluated At the beginning After 6 months' of storage storage Appearance of lyophilizateWhite, compact White, compact Chromatographic purity of lyophilizate:
Oxalic acid (%) 0.10 0.08 Total impurities (%) 0.11 0.16 L-isomer (%) < 0.1 < 0.1 Water content in lyophilizate0.8 1.0 (%) Appearance of solution Clear according to Clear according after Ph. Eur. to Ph.
dissolution of lyophilizateArt. 2.2.1 Eur. Art. 2.2.1 (3%
aqueous solution) Contamination of lyophilizateWithout visible particlesWithout visible solution particles The percentages given in Table 1 are % by weight.
Ezample 4 This Example studies the stability of the pharmaceutical composition prepared in Example 2 when stored at 40 °C and 75% relative humidity. The obtained results are given in Table 2 below.
Table 2 Parameter evaluated At the beginning of After 6 months' storage storage Appearance of lyophilizateWhite, compact White, compact Chromatographic purity of lyophilizate:
Oxalic acid (%) 0.10 < 0.1 Total impurities (%) 0.11 0.12 L-isomer (%) < 0.1 < 0.1 Water content in lyophilizate1.0 1.1 (%) Appearance of solution Clear according to Clear according after Ph. Eur. to Ph. Eur.
dissolution of lyophilizateArt. 2.2.1 Art. 2.2.1 (3%
aqueous solution) Contamination of lyophilizateWithout visible particlesWithout visible solution particles The percentages given in Table 2 are % by weight.
Background of the Invention Oxaliplatin (named according to the INN nomenclature as oxaliplatinum) has been prepared for the first time in the optically pure form in 1978 by isolation from a mixture of isomers [ J.
Clin. Hematol. Oncol. 1977, 7(1), 197-210]. Oxaliplatin is chemically the {trans-(-)-1,2-cyclohexanediamine}-(oxalato)platinum(II) complex of formula I
O
(I) 'NH2 O
Oxaliplatin is a cytostatic agent used in treatment of testicular and ovarial tumors, malignant melanoma, bronchogenic carcinoma and especially of metastazing colon carcinoma in combination with fluoropyrimidines. In comparison with the hitherto used cisplatinum, oxaliplatin exhibits lower nefrotoxicity and a broader spectrum of antitumor activity.
Oxaliplatin is generally applied in doses 100 to 135 mg/m2 in the form of 2 to 6 hours' infusion. The infusion solution is prepared by dilution of the final drug form with 5% aqueous solution of glucose.
Within the framework of the prior art there was described a series of liquid drug forms of oxaliplatin based on its aqueous solutions which however for their insufficient stability so far have not found application. The cause of this instability is the known fact that oxaliplatin hydrolytically decomposes under formation of toxic platinum aquacomplexes. The only stable drug form of oxaliplatin known so far is a powder composition obtained by freeze-drying in vacuo (lyophilization). Beside oxaliplatin, this dry powdery composition contains a carrier consisting of lactose which ensures the cohesion of the dry oxaliplatin matrix formed by freeze-drying in vacuo and prevents its cracking, which otherwise would result in escape of part of the oxaliplatin from vials in which the freeze-drying takes place. The substantial drawback of the hitherto used lactose carrier, which is an animal product, is the risk of viral contamination of the pharmaceutical composition by viruses that may be present in lactose.
Recently, reduction of the risk of such viral contamination, especially of transfer of animal spongiform encephalopathy, represents a current problem concerning most drug forms that contain auxiliary components of animal, particularly bovine origin. Lactose, hitherto employed in oxaliplatin pharmaceutical compositions, exhibits very good cryoprotective effects and its replacement with another suitable carrier under preservation of properties of oxaliplatin lyophilizate and economy of the freeze-drying process so far has not been satisfactorily solved.
Summary of the Invention The above-mentioned desired replacement of the lactose carrier with another carrier which in principle eliminates the mentioned risk of viral contamination is solved by the pharmaceutical composition according to the present invention, prepared by freeze-drying in vacuo, that contains oxaliplatin as the active component together with a pharmaceutically acceptable carrier, the said composition being characterized in that it contains at least one alcoholic sugar of non-animal origin as a Garner, the ratio of oxaliplatin to this alcoholic sugar or alcoholic sugars of non-animal origin being 1:3 to 1:7 by weight.
Preferably, the pharmaceutical composition according to the invention contains oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin in a ratio 1:5 by weight.
In a pharmaceutical composition according to the invention, the preferred alcoholic sugar of non-animal origin is mannitol.
The present invention also relates to the method of manufacturing of the above mentioned pharmaceutical composition, characterized in that a sterile aqueous solution of oxaliplatin and of at least one alcoholic sugar of non-animal origin, containing oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of no-animal origin in a weight ratio 1:3 to 1:7 with total concentration of the mentioned compounds 2.8 to 3.2 % by weight, is introduced into a vial in a volume equal to at most 60 % of the available vial volume, whereupon the content of the vial is cooled to 2 to 8 °C, then freezed under linear temperature drop of 0.1 to 0.5 °C/min to a final temperature of -35 to -45 °C, left aside at this temperature for 1 to 6 hours and then subjected to freeze-drying in vacuo.
Finally, the invention also relates to the above mentioned pharmaceutical composition for application in treatment of tumors sensitive to oxaliplatin.
After dissolution in a suitable pharmaceutically acceptable solvent, the pharmaceutical composition according to this invention affords a clear solution which contains neither undissolved material nor turbidity and which is thus particularly suitable for parenteral application. The composition according to the invention can be readily prepared, is highly stable and its application does not represent any risk of viral contamination.
The method according to the present invention solves problems that would occur in the case of mere replacement of lactose by mannitol without changing the existing mode of working with lactose. During workup of solutions in which lactose is simply replaced with mannitol, the lyophilizate often escapes from the vials and the glass vials crack as the result of increased mechanical tension due to the changing volume of the freezed solution, which is particularly manifested by falling away of the vial bottom during the freeze-drying procedure.
It has been found that the temperature mode of the freezing procedure according to the invention significantly eliminates the mentioned vial cracking in the course of the freeze-drying procedure. Thus, it was found that in order to achieve an optimal freeze-drying rate the total concentration of oxaliplatin and of at least one alcoholic sugar in the aqueous solution before the freeze-drying must be 2.8 to 3.2 % by weight. Further, it was found that the vials can be filled with the sterile solution of oxaliplatin and mannitol in the mentioned weight ratio in a volume up to 60 % of the available vial volume without change of the lyophilizate quality, without escape of the lyophilizate from the vials, and without cracking of the vials, which represents a very advantageous solution from the viewpoint of utilization of capacity of the freeze-drying equipment.
For its properties, the pharmaceutical composition according to the invention is particularly suitable for application in treatment of tumors sensitive to oxaliplatin.
In the following part of the description the invention will be explained in detail using individual examples of execution, that are only illustrative, without limiting in any way the scope of the invention.
Examples Example 1 Under GMP conditions, 0.50 kg of oxaliplatin (pharmacopoeia quality) and 2.50 kg of mannitol (pharmacopoeia quality) are gradually dissolved at 20 to 25 °C
in 70 kg of water.
The obtained solution is sterilized by filtration through a 0.22 ~.m filter and filled into colourless clear vials for antibiotics of the first hydrolytic class, type 20 H (Saint Gobain Desjonqueres) the amount of the solution corresponding to 50 mg of the dissolved active component per vial. The filled vials are equipped with stoppers for freeze-drying and placed into a freeze-drying chamber, pre-cooled to 5 °C. After thermal equilibration of the solution in the vial with the environment, the solution in the vial is slowly freezed (linear temperature drop of 0.2 °C/min) to the final temperature of -40 °C. The frozen solution is left at this temperature for 4 h, whereupon it is subjected to freeze-drying in vacuo.
The obtained lyophilizate has a white compact form and contains 0.8 % by weight of water.
Dissolution of the obtained material gives a clear solution, in accord with Ph. Eur. Art. 2.2.1.
Example 2 Under GMP conditions, 0.50 kg of oxaliplatin (pharmacopoeia quality) and 2.50 kg of mannitol (pharmacopoeia quality) are gradually dissolved at 20 to 25 °C
in 70 kg of water.
The obtained solution is sterilized by filtration through a 0.22 pm filter and filled into colourless clear vials for antibiotics of the first hydrolytic class, type 20 H (Saint Gobain Desjonqueres) the amount of the solution corresponding to 100 mg of the dissolved active component per vial. The filled vials are equipped with stoppers for freeze-drying and placed into a freeze-drying chamber, pre-cooled to 5 °C. After thermal equilibration of the solution in the vial with the environment, the solution in the vial is slowly freezed (linear temperature drop of 0.2 °C/min) to the final temperature of -40 °C. The frozen solution is left at this temperature for 4 h, whereupon it is subjected to freeze-drying in vacuo.
The obtained lyophilizate has a white compact form and contains 1.0 % by weight of water.
Dissolution of the obtained material gives a clear solution, in accord with Ph. Eur. Art. 2.2.1.
Example 3 This Example studies the stability of the pharmaceutical composition prepared in Example 1 when stored at 40 °C and 75% relative humidity. The obtained results are given in Table below.
Table 1 Parameter evaluated At the beginning After 6 months' of storage storage Appearance of lyophilizateWhite, compact White, compact Chromatographic purity of lyophilizate:
Oxalic acid (%) 0.10 0.08 Total impurities (%) 0.11 0.16 L-isomer (%) < 0.1 < 0.1 Water content in lyophilizate0.8 1.0 (%) Appearance of solution Clear according to Clear according after Ph. Eur. to Ph.
dissolution of lyophilizateArt. 2.2.1 Eur. Art. 2.2.1 (3%
aqueous solution) Contamination of lyophilizateWithout visible particlesWithout visible solution particles The percentages given in Table 1 are % by weight.
Ezample 4 This Example studies the stability of the pharmaceutical composition prepared in Example 2 when stored at 40 °C and 75% relative humidity. The obtained results are given in Table 2 below.
Table 2 Parameter evaluated At the beginning of After 6 months' storage storage Appearance of lyophilizateWhite, compact White, compact Chromatographic purity of lyophilizate:
Oxalic acid (%) 0.10 < 0.1 Total impurities (%) 0.11 0.12 L-isomer (%) < 0.1 < 0.1 Water content in lyophilizate1.0 1.1 (%) Appearance of solution Clear according to Clear according after Ph. Eur. to Ph. Eur.
dissolution of lyophilizateArt. 2.2.1 Art. 2.2.1 (3%
aqueous solution) Contamination of lyophilizateWithout visible particlesWithout visible solution particles The percentages given in Table 2 are % by weight.
Claims (5)
1. A pharmaceutical composition prepared by freeze-drying in vacuo, containing oxaliplatin as the active component and a pharmaceutically acceptable carrier, characterized in that the carrier is at least one alcoholic sugar of non-animal origin, the weight ratio of oxaliplatin to the alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin being 1:3 to 1:7.
2. The pharmaceutical composition according to Claim 1, characterized in that it contains oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin in a weight ratio 1:5.
3. The pharmaceutical composition according to Claims 1 or 2, characterized in that the alcoholic sugar of non-animal origin is mannitol.
4. A method of manufacturing of pharmaceutical composition according to Claim 1, characterized in that a sterile aqueous solution of oxaliplatin and of at least one alcoholic sugar of non-animal origin, containing oxaliplatin and an alcoholic suger of non-animal origin or alcoholic sugars of non-animal origin in a weight ratio 1:3 to 1:7, with total concentration of the mentioned compounds 2.8 to 3.2 % by weight, is introduced into a vial in a volume amount equal to at most 60 vol% of the available vial volume, whereupon the content of the vial is cooled to a temperature of 2 to 8 °C, then freezed under linear temperature drop of 0.1 to 0.5 °C/min to a final temperature of -35 to -45 °C, left at this temperature for 1 to 6 hours and then subjected to freeze-drying in vacuo.
5. The pharmaceutical composition according to any of Claims 1 to 3 for use in the treatment of tumors sensitive to oxaliplatin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZPV2003-2367 | 2003-09-02 | ||
| CZ20032367A CZ300795B6 (en) | 2003-09-02 | 2003-09-02 | Pharmaceutical composition and process for its preparation |
| PCT/CZ2004/000053 WO2005020876A2 (en) | 2003-09-02 | 2004-08-31 | Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2537610A1 true CA2537610A1 (en) | 2005-03-10 |
Family
ID=34256928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002537610A Abandoned CA2537610A1 (en) | 2003-09-02 | 2004-08-31 | Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1663106A2 (en) |
| CA (1) | CA2537610A1 (en) |
| CZ (1) | CZ300795B6 (en) |
| PL (1) | PL366975A1 (en) |
| RU (1) | RU2329052C2 (en) |
| WO (1) | WO2005020876A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ300664B6 (en) * | 2007-01-22 | 2009-07-15 | Pliva-Lachema A. S. | Sterile liquid pharmaceutical composition and process for preparing thereof |
| KR20090102844A (en) * | 2007-01-22 | 2009-09-30 | 플리바-라케마 에이. 에스. | Oxaliplatin pharmaceutical composition with alcoholic sugar-based buffer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5416394A (en) * | 1992-11-24 | 1994-06-22 | Debiopharm S.A. | Cisplatinum/oxaliplatinum combination |
| GB9804013D0 (en) * | 1998-02-25 | 1998-04-22 | Sanofi Sa | Formulations |
| CN1170533C (en) * | 1999-08-30 | 2004-10-13 | 德比奥法姆股份有限公司 | Pharmaceutically stable oxaliplatinum preparation for parenteral administration |
| DE10314377A1 (en) * | 2003-03-28 | 2004-10-07 | Stada Arzneimittel Ag | Pharmaceutical composition useful for tumor therapy comprises water, oxaliplatin and an acid other than oxalic acid |
-
2003
- 2003-09-02 CZ CZ20032367A patent/CZ300795B6/en not_active IP Right Cessation
-
2004
- 2004-04-05 PL PL04366975A patent/PL366975A1/en not_active Application Discontinuation
- 2004-08-31 EP EP04762305A patent/EP1663106A2/en not_active Withdrawn
- 2004-08-31 RU RU2006110563/15A patent/RU2329052C2/en active
- 2004-08-31 WO PCT/CZ2004/000053 patent/WO2005020876A2/en active Application Filing
- 2004-08-31 CA CA002537610A patent/CA2537610A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005020876A3 (en) | 2005-06-09 |
| WO2005020876A2 (en) | 2005-03-10 |
| RU2329052C2 (en) | 2008-07-20 |
| EP1663106A2 (en) | 2006-06-07 |
| CZ300795B6 (en) | 2009-08-12 |
| PL366975A1 (en) | 2005-03-07 |
| RU2006110563A (en) | 2006-08-10 |
| CZ20032367A3 (en) | 2005-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10322183B2 (en) | Pharmaceutical formulations of ecteinascidin compounds | |
| EP2624818B1 (en) | Bortezomib formulations stabilised with boric acid | |
| AU2020244613B2 (en) | Methods for treatment of diseases | |
| CA1211372A (en) | Pharmacological compositions based on cisplatinum and method for obtaining same | |
| JP6869941B2 (en) | A method for producing a lyophilized pharmaceutical composition having a certain content of mitomycin C. | |
| CN102512378B (en) | Stable and safe oxiracetam pharmaceutical composition for injection | |
| CN102258531A (en) | Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof | |
| JPH03193735A (en) | Stabilized composition of glycopeptide-based antibiotic | |
| US20060275331A1 (en) | Pharmaceutical composition, method of manufacturing and therapeutic use thereof | |
| CN104414977A (en) | Artesunate and L-arginine composition for injection and preparation method thereof | |
| CA2537610A1 (en) | Pharmaceutical composition, method of manufacturing and therapeutic use thereof | |
| CN108743527B (en) | Tirofiban hydrochloride injection and preparation method thereof | |
| RU2449791C2 (en) | Lyophilised injected pharmaceutical compostion of semisynthetic alkaloids vinca and carbohydrates, stable at room temperature | |
| JP2022081630A (en) | Freeze-dried composition containing benzoazepine compound | |
| JP2012501331A (en) | Camphosfamide formulation and method for producing the same | |
| RU2313346C2 (en) | Pharmaceutical composition | |
| JP2007504177A (en) | Pharmaceutical composition, process for its production and therapeutic use | |
| JPH0321252A (en) | Cysplatin high tension liquid | |
| JP2004269401A (en) | Lyophilized preparation | |
| SU1213973A3 (en) | Method of stabilizing antibacterial alkali-metal salt of 7beta-(alpha-carboxy-alpha-arylacetamido)-7alpha-methoxyl-3-heterocyclothiomethyl-1-dethia-1-oxa-3-cephem-4-carbloxylic acid | |
| US20210137958A1 (en) | Pharmaceutical compositions of decitabine | |
| CN102151249A (en) | Medical composition of vinflunine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |